Keeping in tradition with the U’s commitment to advance the fields of medicine and surgery, our physicians are focusing on regenerative medicine as the next frontier in treating cardiovascular disease. Researchers within the Cardiovascular Center estimate cell therapy will be FDA-approved within three years. The goal of this therapy is to give cells back to the heart in order for it to grow stronger, work harder, and function more like a younger heart. Currently, studies include the potentiality of injecting cardiac repair cells into patients’ hearts to improve function.
This is the first trial of its kind in the United States, providing heart patients who have limited or no other options with a viable treatment. Using some of the best imaging technology, researchers have been able to see improvements in patients within six months after injecting their own cells directly into the left ventricle of the heart during minimally invasive surgery.
To contact us, please use the contact number provided.
Advanced Lung Disease, Cardiothoracic Surgery, Clinical Scientist, Coronary Revascularization, Critical Care, Heart Stem Cell Therapy, Heart Transplant, Lung Transplant, Oncology Surgery, Transcatheter Aortic Valve Replacement (TAVI or TAVR), Valvular Heart Disease
|University Hospital||(801) 587-7946|
Adult Congenital Heart Disease, Cardiac Mechanical Support, Cardiothoracic Surgery, Coronary Revascularization, Heart Failure, Heart Stem Cell Therapy, Heart Transplant, Lung Transplant, Minimally Invasive Heart Surgery, Surgical Ventricular Restoration, Valvular Heart Disease